Table 1 Baseline demographics and characteristics of the patients before and after matching
All patients | p value | Propensity score-matched patients | p value | |||
|---|---|---|---|---|---|---|
Three-port (n = 147) | Single-port (n = 397) | Three-port (n = 143) | Single-port (n = 143) | |||
Age (years) | 55.2 (13.7) | 53.2 (12.6) | 0.108 | 54.8 (13.7) | 54.6 (11.9) | 0.894 |
Sex | < 0.001 | 0.884 | ||||
Male | 30 (20.4%) | 146 (36.8%) | 30 (21.0%) | 29 (20.3%) | ||
Female | 117 (80.3%) | 251 (63.2%) | 113 (79.0%) | 114 (79.7%) | ||
FEV1 (L) | 2.5 (0.7) | 2.6 (0.7) | 0.084 | 2.5 (0.7) | 2.5 (0.6) | 0.552 |
Smoking history | 0.048 | 0.557 | ||||
Current or ever | 16 (10.9%) | 71 (17.9%) | 16 (11.2%) | 13 (9.1%) | ||
Never | 131 (89.1%) | 326 (82.1%) | 127 (88.8%) | 130 (90.9%) | ||
BMI (kg/m2) | 23.1 (3.1) | 23.0 (2.9) | 0.736 | 23.1 (3.1) | 23.2 (2.9) | 0.702 |
Tumor size (cm) | 1.1 (0.5) | 1.1 (0.4) | 0.849 | 1.1 (0.5) | 1.1 (0.4) | 0.374 |
Location | 0.380 | 0.591 | ||||
LUL | 44 (29.9%) | 96 (24.2%) | 41 (28.7%) | 38 (26.6%) | ||
LLL | 19 (12.9%) | 55 (13.9%) | 19 (13.3%) | 24 (16.7%) | ||
RUL | 56 (38.1%) | 147 (37.0%) | 56 (39.2%) | 48 (33.6%) | ||
RML | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
RLL | 28 (19.0%) | 99 (24.9%) | 27 (18.9%) | 33 (23.1%) | ||
Pathology | 0.397 | 0.678 | ||||
AIS | 30 (20.4%) | 103 (25.9%) | 30 (21.0%) | 31 (21.7%) | ||
MIA | 43 (29.2%) | 112 (28.2%) | 43 (30.1%) | 49 (34.3%) | ||
IA | 74(43.5%) | 182(45.8%) | 70 (49.0%) | 63 (44.1%) | ||
Stage | 0.390 | 0.689 | ||||
IA1 | 40 (27.2%) | 86 (21.7%) | 37 (25.9%) | 32 (22.4%) | ||
IA2 | 34 (23.1%) | 96 (24.2%) | 33 (23.1%) | 31 (21.7%) | ||